The use of carbonic anhydrase inhibitors in the management of chronic simple glaucoma is commonplace. A number of reports on the long-term use of these drugs have appeared in the literature1,2 and suggest that no local ocular toxity develops. The commonest cause of failure is the systemic side-effects which necessitate discontinuation of the drug. A truly refractory state to the drug is unusual.
Ethoxzolamide (Cardrase) is a new potent carbonic anhydrase inhibitor which has been reported on in the treatment of glaucoma by Posner,3 and its effects on intraocular pressure and ocular dynamics in normal and glaucomatous eyes have been studied by Drance.4
Ethoxzolamide has been used in this clinic as an adjunct in the treatment of patients with chronic simple glaucoma over the past two years. This paper is a report on the use of this drug in the long-term management and control of patients with
DRANCE SM. Ethoxzolamide (Cardrase) in the Management of Chronic Simple Glaucoma. Arch Ophthalmol. 1960;64(3):433-437. doi:10.1001/archopht.1960.01840010435017